[Enalapril in patients with diabetes mellitus type I with microalbuminuria without hypertension].
The studies included 18 normotensive patients with diabetes mellitus type I (mean age 29 years) and constant microalbuminuria (UAE-30 - 300 mg/24 hours). Group A consisted of 10 patients treated with enalapril, and group B--10 patients given placebo. Glomerular filtration rate, ERPF, and UAE were measured before and after 6 months of therapy. UAE decreased significantly in patients of group A (p = 0.02) after 6 months while evident proteinuria was seen in two patients of group B. Arterial blood pressure dropped in patients of group A (131/84 vs 122/78 mm Hg), and increased significantly in patients of group B (126 +/- 8 vs 136 +/- 15 mm Hg; p < 0.05). Blood flow through kidneys improved (p = 0.02) and renal vascular resistance decreased (p = 0.02) in patients of group A. The obtained results suggest that enalapril may prevent diabetic nephropathy in diabetics with constant microalbuminuria.
Semetkowska-Jurkiewicz
E
E
II Kliniki Chorób Wewnetrznych Instytutu Chorób Wewnetrznych AM, Gdańsku.
Milewski
J
J
Krupa-Wojciechowska
B
B
Wójcikowski
C
C
Horoszek-Maziarz
S
S
D000328:Adult; D000419:Albuminuria / Q000188:drug therapy*; D003922:Diabetes Mellitus, Type 1 / Q000188:drug therapy*; D003928:Diabetic Nephropathies / Q000188:drug therapy*; D004656:Enalapril / Q000627:therapeutic use*; D005260:Female; D006801:Humans; D008297:Male
D004656:Enalapril
Enalapryl u chorych na cukrzyce typu I z mikroalbuminuria bez nadciśnienia tetniczego.